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 Background Breast cancer frequently metastasizes to the brain, colonizing a neuro-inflammatory microenvironment. The 
molecular pathways facilitating this colonization remain poorly understood.
 Methods Expression profiling of 23 matched sets of human resected brain metastases and primary breast tumors by two-
sided paired t test was performed to identify brain metastasis–specific genes. The implicated DNA repair genes 
BARD1 and RAD51 were modulated in human (MDA-MB-231-BR) and murine (4T1-BR) brain-tropic breast cancer 
cell lines by lentiviral transduction of cDNA or short hairpin RNA (shRNA) coding sequences. Their functional 
contribution to brain metastasis development was evaluated in mouse xenograft models (n = 10 mice per group).
 Results Human brain metastases overexpressed BARD1 and RAD51 compared with either matched primary tumors (1.74-
fold, P < .001; 1.46-fold, P < .001, respectively) or unlinked systemic metastases (1.49-fold, P  =  .01; 1.44-fold, 
P =  .008, respectively). Overexpression of either gene in MDA-MB-231-BR cells increased brain metastases by 
threefold to fourfold after intracardiac injections, but not lung metastases upon tail-vein injections. In 4T1-BR 
cells, shRNA-mediated RAD51 knockdown reduced brain metastases by 2.5-fold without affecting lung metasta-
sis development. In vitro, BARD1- and RAD51-overexpressing cells showed reduced genomic instability but only 
exhibited growth and colonization phenotypes upon DNA damage induction. Reactive oxygen species were pre-
sent in tumor cells and elevated in the metastatic neuro-inflammatory microenvironment and could provide an 
endogenous source of genotoxic stress. Tempol, a brain-permeable oxygen radical scavenger suppressed brain 
metastasis promotion induced by BARD1 and RAD51 overexpression.
 Conclusions BARD1 and RAD51 are frequently overexpressed in brain metastases from breast cancer and may constitute a 
mechanism to overcome reactive oxygen species–mediated genotoxic stress in the metastatic brain.
  J Natl Cancer Inst (2014) 106(7): dju145
Brain metastases represent one of the most devastating conse-
quences of breast cancer (1,2). Approximately 35% of patients with 
metastatic HER2 (human epidermal growth factor receptor 2)–
positive or triple negative (TN; hormone receptor negative, HER2 
normal) tumors develop brain metastases (3,4), likely the result of 
systemic responses to chemotherapy at extracranial sites allowing 
more time for brain relapse, the inability of most anticancer agents 
to cross the blood–tumor barrier in effective concentrations, and 
increased diagnostic imaging. Brain metastases are also common 
in lung cancer and melanoma and will likely increase in other can-
cer types as effective systemic therapies emerge. Brain metastasis 
patients experience seizures, impaired motor function, and cog-
nitive losses; brain metastases increasingly contribute to patient 
deaths (5).
The brain is an unusual environment for cancer cells, and unique 
molecular pathways are believed to regulate brain colonization. The 
brain is protected by the blood–brain barrier, which may remain 
partially patent in metastases (6,7). The brain metastatic micro-
environment is also modified by a neuro-inflammatory response 
containing activated microglia and astrocytes (8,9), and coloniza-
tion is punctuated by periods of dormancy (10,11). To date, only 
ST6GALNAC5 has been reported to confer brain-specific metas-
tasis (12).
To better understand the pathways that promote human brain 
metastasis, we performed cancer-specific gene expression pro-
filing on rare sets of primary breast tumors and resected brain 
metastases from the same patients. Overexpression of DNA 
double-strand break (DSB) repair genes, including BARD1 and 
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RAD51, were observed in the matched brain metastases. DNA 
DSB, generated by genotoxic insults or DNA replication fork col-
lapse from attempted traversal of various lesions, can be repaired 
nonfaithfully by nonhomologous end joining or faithfully by 
homologous recombination (HR). RAD51 is a critical component 
of the HR process, which, by forming a nucleofilament on the 3’ 
ends of single-stranded DNA at the break site, along with various 
comediators, facilitates invasion and annealing to the homolo-
gous DNA template on the sister chromatid [reviewed in (13)]. 
In addition, RAD51 has important other HR-related (14–19) 
and non-HR functions (16,20–23). Cancer phenotypic responses 
of altered RAD51 expression have been reported in models of 
chemotherapy (24–26) and radiation (27,28). To the best of our 
knowledge, no in vivo phenotypes have been reported for RAD51 
overexpression (29).
BRCA1-associated RING domain protein 1 (BARD1) is a heter-
odimeric binding partner of the breast cancer type 1 susceptibility 
protein (BRCA1), with which it interacts through their N-terminal 
RING finger domains (30,31). This interaction is essential for the 
E3 ubiquitin ligase activity (32,33) and tumor suppressor functions 
of BRCA1 (34). Specifically, BARD1 facilitates BRCA1 nuclear 
translocation for DNA repair (35), enhances BRCA1 DNA bind-
ing (36), and may be required for BRCA1 function in homology-
dependent DNA repair and maintaining genomic integrity (37). 
During S and G2 cell-cycle phase and upon DNA damage induc-
tion, the BARD1/BRCA1 heterodimer assembles into nuclear foci 
in protein complexes that also contain BRCA2 and the pivotal HR 
protein RAD51 (38,39). At the sites of DNA damage, this super-
complex directs HR through the BRCA1–BRCA2 linker protein 
PALB2 (40–42). BRCA1-independent functions of BARD1 have 
also been reported (43,44). Functional in vivo phenotypes of 
BARD1 overexpression have not been described.
We examined whether the unexpected overexpression of BARD1 
or RAD51 in human brain metastases functionally promotes 
experimental brain or lung metastasis in mouse xenograft models. 
Further, we address our hypothesis that BARD1 and RAD51 over-
expression enhances brain metastasis development, specifically by 
providing resistance against the genotoxic effects of reactive oxy-
gen species (ROS) produced in the inflammatory metastatic brain.
Methods
Gene Expression Analysis
Archived, anonymized, formalin-fixed, paraffin-embedded sample 
pairs of brain metastases and primary tumors, each from patients 
treated between 1996 and 2006 in six Polish institutions were evalu-
ated. This study was approved by the Institutional Review Board of 
the coordinating centers (Medical University of Gdansk, Poland; 
Indiana University). Gene expression of 23 matched sets of primary 
breast tumors and brain metastases were evaluated using cDNA-
mediated annealing, selection, extension, and ligation (DASL) 
analysis according to the manufacturer’s instructions (Sentrix 
Universal Array; Illumina, San Diego, CA). More details appear 
in the Supplementary Methods (available online). This study used 
archival formalin-fixed, paraffin-embedded blocks, and all personal 
data were made anonymous and coded; therefore patient consent 
was not sought.
Cell Lines
The human MDA-MB-231 brain-tropic cell line (MDA-MB-
231-BR) and murine 4T1-BR brain-tropic line were described 
previously (6,45). Human BARD1 and RAD51 cDNAs were sub-
cloned into lentiviral vectors pCDH-CMV-MCS-EF1 (Systems 
Biosciences, Mountain View, CA); empty vector served as con-
trol. More details about overexpression and knockdown protocols 
appear in the Supplementary Methods (available online).
In Vitro Assays
All in vitro assays were performed using standard protocols and, 
where applicable, following the recommendations of product man-
ufacturers. Detailed description of assay procedures, reagents, and 
antibodies appear in the Supplementary Methods (available online).
Mouse Models
Experiments were carried out under an approved Animal Use 
Agreement with the National Cancer Institute. Intracardiac-
injected brain metastasis models were performed, and metastases 
were quantified as previously described (45,46). For these brain 
metastasis models, female NCr nu/nu mice aged 5 to 7 weeks 
(Charles River, Frederick, MD) were inoculated in the left cardiac 
ventricle with 175 000 human MDA-MB-231-BR cells or 50 000 
murine 4T1-BR cells under isoflurane/oxygen anesthesia. Ten 
mice per group were injected. Mice were killed under carbon diox-
ide asphyxiation at onset of signs of tumor-induced morbidity, such 
as weight loss, ataxia, and/or paralysis.
For lung metastasis models, female NCr nu/nu mice or BALB/c 
mice aged 5 to 7 weeks (Charles River, Frederick, MD) were tail-
vein inoculated with 50 000 MDA-MB-231-BR or 10 000 4T1-BR 
cells, respectively. Ten mice per group were injected. Upon signs of 
tumor-induced morbidity, mice were killed under carbon dioxide 
asphyxiation. Lungs were preserved in Bouin’s solution, and lung 
surface metastases were counted.
Additional details on brain metastasis and lung metastasis assays, 
as well as tempol feeding study, appear in the Supplementary 
Methods (available online).
Statistical Analysis
BARD1 and RAD51 expression changes between primary tumors 
and brain metastases by DASL were compared by paired t test of 
log2-tranformed, normalized expression values. BARD1 and RAD51 
expression between brain metastases and systemic metastases was 
compared by unpaired t test on RMA-normalized, log2-transformed 
expression values. The P values in Table 1 were adjusted for multiple 
comparisons of 42 DNA repair–related genes examined in the DASL 
array using Bonferroni–Holm correction for multiple comparisons.
Distributions of continuous variables were examined for nor-
mality using Shapiro–Wilk tests. If normal, bicategorical data were 
compared with unpaired t tests with equal variances or corrected for 
unequal variances by Welch correction. Multicategorical data were 
globally examined by analysis of variance, and each experimental 
group was compared with unified control group using Dunnett’s mul-
tiple comparisons test. Otherwise, bicategorical data were compared 
by Mann–Whitney test, and multicategorical data were globally 
examined by Kruskal–Wallis test, comparing individual experimen-
tal groups with a unified control group using Dunnett’s multiple 
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comparisons test. For clonogenic survival assays, multiple unpaired 
t tests were performed using the Holm–Sidak method (alpha = 0.05). 
All tests were two-sided, and P values less than .05 were considered 
statistically significant. All statistical analyses were performed using 
GraphPad Prism version 6.0 software (GraphPad, La Jolla, CA).
results
BARD1 and RAD51 Expression in Human Brain 
Metastases of Breast Cancer
Twenty-three pairs of resected primary tumors and brain metas-
tases from the same patients were profiled for the mRNA expres-
sion of 502 cancer-related genes (Supplementary Table 1, available 
online). A general DNA repair phenotype was apparent for brain 
metastases of breast cancer. Of 42 DNA repair genes assayed, 25 
had statistically significantly higher expression in brain metastases 
compared with primary tumors, with HR pathway genes exhibiting 
the most robust signals (Table 1). Our functional studies focused 
on BARD1 and RAD51 because both proteins coexist in a critical 
HR DNA repair supercomplex (47,48) and physically interact with 
several other HR pathway genes overexpressed in brain metastases 
in this dataset, such as BRCA1, BRCA2, and RAD54B. Furthermore, 
both proteins have previously been implicated in brain metastatic 
progression as part of a 13-gene signature predictive of rapid brain 
relapse in HER2-positive metastatic breast cancer patients (49).
Analysis of all 23 sample pairs showed consistent overexpres-
sion of both BARD1 (1.74-fold; P < .001) and RAD51 (1.46-fold; 
P < .001) in brain metastases compared with matched primary 
tumors (Figure 1, A and B). Trends of differential BARD1 and RAD51 
expression were observed in matched sets of TN tumors (2.40-fold, 
P = .04; 1.67-fold, P = .09, respectively) and HER2-positive tumors 
(1.64-fold, P = .008; 1.49-fold, P < 0.001, respectively) (Figure 1, C 
and D). Comparable expression levels of both genes were observed 
in estrogen receptor–positive tumor sample sets. Quantitative real-
time polymerase chain reaction was performed to assess RAD51 
expression in 13 of the 23 sample pairs for which sufficient RNA was 
available. This analysis confirmed RAD51 overexpression in brain 
metastases samples compared with primary tumors, with a median 
fold change of 2.1 (P  =  .02) (Supplementary Figure  1A, available 
online) and with general agreement between the two mRNA quanti-
fication methodologies (Supplementary Figure 1B, available online).
To investigate whether overexpression of BARD1 and RAD51 
is a specific feature of breast cancer brain metastases or is gener-
ally associated with breast cancer spread, we compared BARD1 and 
RAD51 expression in breast cancer metastases at different organ 
sites (brain, lung, and bone) in a publically available microarray 
dataset (GEO No. GSE14017) (50). BARD1 and RAD51 were 
overexpressed (1.49-fold, P = .01; 1.44-fold, P = .008, respectively) 
in brain metastases compared with systemic (lung/bone) metastases 
(Figure 1, E and F).
Table 1. Fold changes (FC) and P-values (P) for DNA repair genes overexpressed in the brain metastases compared with the primary breast 
tumors of the same patients in 23 matched sample sets by cDNA-mediated annealing, selection, extension, and ligation (DASL) array analysis*
DNA repair process Symbol FCall† Pall‡ Pall§ FCTN PTN FCHER2+ PHER2+ FCER+ PER+
Homologous recombination RAD51 1.46 <.001 .004 1.67 .09 1.49 <.001 1.11 .43
Homologous recombination BARD1 1.74 <.001 .02 2.40 .04 1.64 .007 1.20 .58
Homologous recombination BRCA1 1.31 .004 .15 1.31 .39 1.34 .01 1.23 .28
Homologous recombination BRCA2 1.50 .004 .14 1.78 .08 1.53 .03 1.10 .76
Homologous recombination RAD54B 1.59 <.001 .004 1.65 .04 1.71 .004 1.26 .25
Homologous recombination RAD54L 1.26 .02 .48 1.28 .23 1.38 .02 0.96 .52
Homologous recombination XRCC2 1.51 <.001 .001 1.74 .01 1.54 .002 1.19 .58
Base excision repair LIG3 1.42 .04 .84 1.92 .14 1.34 .12 1.03 .88
Base excision repair XRCC1 1.30 .02 .62 1.57 .16 1.26 .10 1.07 .71
Mismatch excision repair MSH2 1.46 .03 .76 1.83 .34 1.42 .02 1.10 .86
Mismatch excision repair MSH6 1.14 .03 .68 1.20 .11 1.17 .06 1.01 .91
Mismatch excision repair PMS1 1.69 .002 .06 2.60 .03 1.49 .03 1.06 .33
Nonhomologous end-joining XRCC4 1.24 .03 .76 1.44 .12 1.24 .13 1.01 .96
Nonhomologous end-joining XRCC5 1.23 .05 .82 1.28 .19 1.28 .11 1.03 .98
Nucleotide excision repair CCNH 1.23 .02 .61 1.40 .02 1.26 .12 0.94 .28
Nucleotide excision repair CDK7 1.28 .008 .26 1.38 .02 1.28 .11 1.15 .56
Nucleotide excision repair ERCC4 1.15 .03 .75 1.20 .08 1.22 .03 0.89 .06
Nucleotide excision repair ERCC5 1.75 .04 .88 3.23 .07 1.31 .22 1.05 .86
Nucleotide excision repair LIG1 1.79 .004 .14 2.79 .07 1.52 .03 1.23 .58
Nucleotide excision repair XPA 1.47 .01 .36 2.21 .11 1.30 .02 1.00 .90
Repair of DNA crosslinks and adducts FANCA 1.62 .03 .72 1.85 .65 1.50 .01 1.63 .34
Repair of DNA crosslinks and adducts FANCG 1.25 <.001 .02 1.44 .04 1.26 .005 1.02 .85
DNA damage response CHEK1 1.53 .03 .79 1.64 .47 1.52 .08 1.43 .33
DNA polymerases (catalytic subunits) PCNA 1.29 .01 .37 1.18 .28 1.38 .04 1.19 .45
Disease sensitivity to DNA damage BLM 1.55 .009 .28 1.42 .52 1.75 .01 1.25 .37
* Analyses are shown for all 23 matched sets (all), and by subtypes: triple negative (TN), human epidermal growth factor receptor 2 overexpressing/amplified 
(HER2+), and estrogen receptor positive (ER+) primary breast tumors. Bold rows indicate the genes functionally evaluated in the manuscript.
† Fold change (FC) comparing genes expression in brain metastases with matched primary tumors.
‡ P values for gene expression comparisons between brain metastases and matched primary tumors. P values were calculated using two-sided, paired t test of log2-
tranformed, normalized expression values.
§ P values adjusted for multiple comparisons of 42 DNA repair–related genes examined in the cDNA-mediated annealing, selection, extension, and ligation array array 
using Bonferroni–Holm correction for multiple comparisons.
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Figure 1. Expression of the DNA repair genes BARD1 and RAD51 in 
brain metastases from breast cancer. Box and whisker plots show 
expression of BARD1 (A) and RAD51 (B) in a set of 23 resected 
brain metastases compared with their matched primary tumors, as 
detected by cDNA-mediated annealing, selection, extension, and 
ligation assay. The Box represents the 25th to 75th percentile, the 
whiskers represent the minimum and maximum values, and the dots 
represent individual patient data points. Subset analyses of BARD1 
(C) and RAD51 (D) expression are presented by tumor subtype. 
Differential expression in primary tumors vs brain metastases was 
assessed separately for patients with triple-negative (TN), human 
epidermal growth factor receptor 2–positive (HER2+), and estrogen 
receptor-positive (ER+) tumors. The line graphs show expression 
changes between primary tumors and brain metastases for indi-
vidual matched pairs. For (A–D), P values were determined by two-
sided, paired t tests. E and F) In a publically available microarray 
dataset (Gene Expression Ominbus accession number GSE14017) of 
distant breast cancer metastases (n = 15 brain, 4 lung, 10 bone), both 
BARD1 (E) and RAD51 (F) expression in brain metastases was com-
pared with systemic (lung/bone) metastases; box-and-whisker plots 
with median are shown. The Box represents the 25th to the 75th per-
centile, the whiskers represent the minimum and maximum values, 
and the dots represent individual patient data points. P values were 
determined by two-sided, unpaired t tests.
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Effect of BARD1 and RAD51 Overexpression on DNA 
Repair Function and Chemo-Resistance In Vitro
Given the clinical observation that most breast cancer patients 
who develop brain metastases do so after initial chemotherapy 
and extracranial metastatic relapse (51), at least two distinct roles 
for BARD1 and RAD51 overexpression could be envisioned. Their 
overexpression could alter the natural history of breast cancer to 
specifically promote brain metastasis or, alternatively, maintain 
tumor cell survival through rounds of chemotherapy, indirectly 
facilitating brain metastasis. To test a direct effect of BARD1 and 
RAD51 overexpression, we generated stable wild-type human 
BARD1- and RAD51-overexpressing polyclonal populations and 
empty vector-expressing controls in the brain-tropic TN human 
breast carcinoma cell line MDA-MB-231-BR (Figure 2, A and B). 
In vitro, overexpression of both genes increased genomic stabil-
ity under normal culture conditions, evidenced by reductions 
in markers of unrepaired DNA DSBs. As such, BARD1- and 
RAD51-overexpressing transfectants exhibited fewer γ-H2AX 
DNA DSB foci than vector controls (P  =  .006 and P < .001, 
respectively) (Figure 2C), which were enumerated in Geminin-
positive cells as a readout of S to early M cell-cycle phase, when 
sister chromatid availability enables DNA repair by HR (repre-
sentative images of γ-H2AX costaining with Geminin are shown 
in Supplementary Figure  2D, available online). Similarly, both 
BARD1- and RAD51-overexpressing transfectants had fewer 
DNA DSBs, as shown by neutral comet assay (P < .001 and 
P < .001, respectively) (Figure 2D). These reductions in residual 
(unrepaired) DNA DSB loads are consistent with increases in 
DSB repair; consequently, higher rates of HR were observed in 
BARD1 and RAD51 overexpressers compared with vector con-
trols (P < .001 and P < .001, respectively) (Figure 2E). Thus, the 
expression levels of BARD1 and RAD51, were limiting for HR 
in vitro.
Another role of RAD51 is in restarting stalled replication forks, 
which, if unresolved, can disintegrate into DSBs (21). RAD51-
overexpressing MDA-MB-231-BR cells exhibited lower frequen-
cies of replication fork stalling after a 2-hour hydroxyurea block 
compared with vector controls (P = .01) (Supplementary Figure 2A, 
available online), confirming that RAD51 is also limiting for this 
function in vitro.
Despite evidence of increased function in HR, BARD1- and 
RAD51-overexpressing MDA-MB-231-BR cells failed to exhibit 
any distinct phenotypes in proliferation, invasion, or cell-cycle 
distribution under normal culture conditions (Supplementary 
Figure  2, B, C, and F, available online). However, when chal-
lenged with a DNA DSB-inducing agent such as doxorubicin, a 
clonogenic phenotype emerged for both BARD1- and RAD51-
overexpressing MDA-MB-231-BR cells (P < .01 for both genes 
and doses) (Figure 2F). A similar, although less robust protection 
against doxorubicin-induced DNA damage, was noted in a 3-(4,5 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide survival 
assay (Supplementary Figure 2E, available online). Together, these 
in vitro data indicate that BARD1 and RAD51 overexpression in 
MDA-MB-231-BR cells resulted in a functional enhancement of 
HR and DNA repair activity in response to both endogenous and 
chemotherapy-induced DNA damage, but only generated growth 
and survival phenotypes in the latter.
Next, we investigated how BARD1 and RAD51 overexpression 
could functionally enhance DNA DSB repair. We hypothesized 
that their participation in a DNA repair supercomplex was funda-
mental, particularly with regard to BARD1 potentiation of endog-
enous RAD51 function. Figure  3A shows a proposed schematic 
of a DNA DSB repair supercomplex containing BRCA1, which, 
along with its binding partner BARD1, directs BRCA2/RAD51 to 
sites of DNA damage through the mediator protein PALB2 (41). 
The overall expression of these supercomplex proteins was gen-
erally unaffected by overexpression of either BARD1 or RAD51 
under normal culture conditions or upon DNA damage induction 
(Figure  3B). One noteworthy exception was a slight increase in 
PALB2 after BARD1 and RAD51 overexpression under doxorubicin 
treatment (Figure 3B). RAD51 foci formation was absent or infre-
quent in vector-expressing MDA-MB-231-BR cells, but efficient 
assembly of RAD51 foci was observed in both BARD1 and RAD51 
overexpressers (Figure 3, C and D). For the BARD1 overexpressers, 
this was accompanied by upstream assembly of both BARD1 and 
BRCA1 foci. In RAD51 and vector transfectants, however, BARD1 
and BRCA1 foci were largely absent. These patterns are similar 
in the absence and presence of doxorubicin treatment and suggest 
that BARD1 overexpression in MDA-MB-231-BR cells exerts its 
enhancement of HR and DNA repair phenotypes by facilitating 
assembly of endogenous RAD51 into active repair foci (representa-
tive images of the BARD1, BRCA1, and RAD51 foci assemblage 
quantified in Figure  3, C and D, are shown in Supplementary 
Figure 3, A and B, available online).
Effect of BARD1 and RAD51 Overexpression on Brain 
Metastasis Development In Vivo
A direct contribution of BARD1 and RAD51 overexpression to 
brain metastasis development was investigated using an intracar-
diac-injected hematogenous brain metastasis model. Surprisingly, 
both BARD1 and RAD51 overexpression resulted in threefold to 
fourfold increase in brain micrometastases (P = .002 and P = .008, 
respectively) and large brain metastases (P = .01 and P = .02, respec-
tively), the latter corresponding to the minimal unidimensional size 
of a lesion detectable by magnetic resonance imaging in a human 
brain (Figure 4, A and B) (46). No difference in the multiplicity 
of lung surface metastases was apparent upon BARD1 or RAD51 
overexpression using a tail-vein experimental metastasis assay 
(Figure  4C). Additionally, the increase in brain metastases after 
overexpression of both genes was not associated with increased 
proliferation of frankly metastatic cells in vivo, as measured by 
Ki67 proliferation index (Figure 4D).
The effect of BARD1 and RAD51 overexpression was evident 
in initial brain colonization events. MDA-MB-231-BR metasta-
ses developed as clusters of micro- and large metastases in vivo 
(Figure 4E) that likely resulted from clonal expansion of single ini-
tiating cells that eventually coalesced into a single lesion (8). There 
was a 3.5-fold (P = .002 for both genes) increase in brain metastasis 
clusters compared with vector controls (Figure 4F), suggesting that 
both genes increased the number of metastasis-initiating events. 
To address this possibility, we measured the effects of BARD1 and 
RAD51 overexpression on single cancer cell multiplicity in the 
brain—the earliest step of brain colonization. Vector-, BARD1-, 
and RAD51-transfected MDA-MB-231-BR cells were iron oxide 
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labeled to enable single cell identification in sections by Prussian 
blue staining (Figure 5A) at three early time points in the experimen-
tal brain metastasis assay before the development of micrometasta-
ses. No difference was observed between overexpressers and vector 
controls on day 3 after injection (Figure  5B). A  statistical trend 
toward more single cells was apparent on day 7 after injection for 
RAD51 overexpressers (P = .08), which was statistically significant 
for the BARD1-overexpressing group (P  =  .005). Approximately 
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Figure  2. In vitro phenotypes of BARD1 and RAD51 overexpression in 
brain-metastatic MDA-MB-231-BR cells. Western blot was done to confirm 
overexpression of BARD1 (A) and RAD51 (B) in brain metastatic MDA-MB-
231-BR cells. Alpha-Tubulin was used as loading control. Numbers indi-
cate the expression fold changes relative to tubulin. C and D) DNA repair 
proficiency in BARD1 and RAD51 transfectants of MDA-MB-231-BR cells 
was assessed. Means with 95% confidence intervals (CIs) are shown. C) 
DNA double-strand breaks (DSBs) were measured by the mean number 
of γ-H2AX foci observed in S-M phase (Geminin-positive  =  GMNN+). D) 
Frequency of DNA DSBs were quantified by a neutral comet assay, shown 
normalized to vector transfectants. E) Homologous recombination (HR) pro-
ficiency was assessed by quantitative real-time polymerase chain reaction 
assay to detect reconstituted LacZ from two mutated plasmids. Relative HR 
frequency was calculated by delta-delta CT method with reference to prim-
ers detecting mutated plasmids to adjust for transformation efficiency and 
normalized to recombinant LacZ detection in vector controls. The means of 
six triplicate measurements with 95% confidence intervals are shown. Two-
sided, multiplicity adjusted P values shown in (C–E) are based on one-way 
analysis of variance with Dunnett’s correction for multiple comparisons. F) 
Resistance to DNA damage in BARD1 and RAD1 transfectants was meas-
ured by clonogenic survival assays after treatment with 5 nM and 10 nM 
doxorubicin. The mean percentage surviving colonies relative to untreated 
± standard deviation are shown. P values are based on two-sided, unpaired 
t tests corrected for multiple comparisons by the Holm–Sidak method.
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threefold more BARD1- and RAD51-overexpressing MDA-MB-
231-BR cells compared with vector controls were present by day 
12 (P = .04 and P = .001, respectively).
RAD51-overexpressing- and short hairpin RNA (shRNA)–
mediated RAD51 knockdown polyclonal populations with 
appropriate vector controls were produced in brain-tropic deriva-
tives of the 4T1 TN mouse mammary carcinoma cell line 4T1-
BR (Figure 6A). RAD51 overexpression in 4T1-BR cells resulted 
in increased multiplicity of brain micrometastases (P  =  .02) and 
large brain metastases (P = .006) in an intracardiac injected mouse 
A B
C D
BARD1
Figure  3. Effect of BARD1 and RAD51 overexpression on DNA double-
strand break (DSB) repair foci assemblage. A) Schematic representation 
of BRCA1-containing supercomplex, in which BARD1/BRCA1 heterodimer 
directs BRCA2 and RAD51 to sites of DNA DSBs by linker protein PALB2. B) 
Western blot for five BRCA1 supercomplex components (BCRA1, BARD1, 
PALB2, BRCA2, and RAD51) are shown in the absence and presence of the 
DNA-damaging agent doxorubicin (Dox, 100 nM). Alpha-Tubulin was used 
as the loading control. Quantification of BARD1, BRCA1, and RAD51 foci is 
shown, as detected by immunofluorescence in the absence (C) and pres-
ence (D) of 100 nM doxorubicin. Individual foci counts per cell with medians 
are indicated. P values are two-sided and adjusted for multiplicity based on 
Kruskal–Wallice test with Dunn’s correction for multiple comparisons.
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model (Figure 6, B and C). No effect on lung metastases devel-
opment was observed with RAD51 overexpression in 4T1-BR 
cells (Figure  6D). RAD51 knockdown in 4T1-BR cells had the 
opposite effect, reducing the micrometastasis and large metasta-
sis multiplicity compared with scrambled shRNA controls (2.5-
fold; P  =  .001 for both micro- and large metastases) (Figure  6, 
E and F). No detectable differences in the multiplicity of lung 
surface metastases between RAD51 knockdown cells and scram-
bled shRNA controls were observed in 4T1-BR cells (Figure 6G). 
Thus, RAD51 expression levels control experimental brain meta-
static but not lung metastatic potential in vivo.
Effect of BARD1 and RAD51 Overexpression on 
Resistance to Oxidative Stress in the Metastatic Brain
Given the paradox of brain metastasis promotion by BARD1 and 
RAD51 overexpression in the absence of any chemotherapeutic 
DNA DSB induction in vivo, but in vitro evidence that growth 
and colonization phenotypes were dependent on DNA damage 
A B
C D
E F
P = .008
P = .002
NS
NS
P = .02
P = .01
P = .002
P = .002
Figure 4. Effect of BARD1 and RAD51 overexpression in MDA-MB-231-BR 
cells on brain metastasis development. In an intracardiac-injected brain 
metastasis assay, the effect of BARD1 and RAD51 overexpression on 
brain metastasis multiplicity was assessed separately for micrometas-
tases (P = .002 and P = .008, respectively) (A) and large brain metastases 
(P = .02 and P = .01, respectively) (B). Mean counts per section with 95% 
confidence intervals (CIs) are shown. C) An experimental lung metasta-
sis assay of MDA-MB-231-BR after tail-vein injection of vector-, BARD1-, 
and RAD51-transfected tumor cells showed no effect on multiplicity 
of lung surface metastases; individual lung counts with medians are 
shown. NS = not significant. D) No differences are evident in prolifera-
tion indices of brain metastases between BARD1, RAD51, and vector 
transfectants, as assessed by Ki67 staining of brain metastases; mean 
percentage Ki67-positive cells with 95% confidence intervals are pre-
sented. E) A representative image of a brain metastasis cluster formed 
by intracardiac injection of MDA-MB-231-BR cells in immunocompro-
mised mice is depicted. Scale bar = 200 μm. F) The effect of BARD1 and 
RAD51 overexpression on multiplicity of brain metastasis clusters of 
tumor cells was compared with vector control (P = .002 for both com-
parisons). Mean clusters per section with 95% confidence intervals are 
shown. P values presented are two-sided and adjusted for multiplic-
ity based on one-way analysis of variance with Dunnett’s correction 
for multiple comparisons. For all metastasis assays, 10 mice per group 
were injected.
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induction, we hypothesized that endogenous genotoxic stresses 
were present in the brain microenvironment. The brain exhibits 
one of the highest levels of endogenous ROS compared with other 
organs, particularly during inflammatory activation of resident 
microenvironmental cells (52). ROS can induce DNA DSB either 
directly (53) or indirectly by replication fork failure after single-
strand lesions (54). A  prominent neuro-inflammatory response 
forms around brain metastases in both experimental models and in 
human craniotomy specimens, including activated astrocytes and 
microglia (8), and is apparent in brains containing vector control– 
or RAD51-overexpressing metastases (Supplementary Figure 3, A 
and B, available online). ROS were observed in the normal mouse 
brain and were more prominent in MDA-MB-231-BR metasta-
ses and in the adjacent neuro-inflammatory microenvironment of 
the brain metastases (Figure  7A). These observations suggested 
the hypothesis that ROS in the MDA-MB-231-BR cells and 
the neuro-inflammatory microenvironment provide an endog-
enous genotoxic stress, which BARD1 or RAD51 overexpression 
overcomes.
To simulate oxidative stress in vitro, vector-, BARD1-, and 
RAD51-transfected MDA-MB-231-BR cells were repeatedly 
treated with hydrogen peroxide in a clonogenic assay. BARD1 and 
RAD51 overexpressers showed increased resistance to hydrogen 
peroxide treatments at 2.5 μM and 5.0 μM doses (approximately 
corresponding to inhibitory concentrations of 50% and 90% for 
vector controls) in this assay (Figure 7B).
To investigate whether the brain metastasis–promoting pheno-
type of BARD1 and RAD51 overexpression depends on genotoxic 
ROS in the brain, we used the brain-permeable radical scavenger 
tempol, a superoxide dismutase mimic (55). Mice injected with 
vector-, BARD1-, or RAD51-overexpressing MDA-MB-231-BR 
cells were randomized to chow containing tempol admixed with a 
flavor additive or a normal control diet containing the flavor addi-
tive. Dihydroethidium (DHE) staining of ROS in brain metastasis 
sections (Figure  7C) indicated that the tempol diet reduced the 
amount of ROS in the brain lesions and immediate microenviron-
ment compared with control diet–fed animals; thus, tempol hit 
its intended target in vivo. In addition to the radical scavenging 
effects of tempol, the drug had some antiproliferative properties 
(Supplementary Figure 3C, available online), which were nondif-
ferential with respect to transfection status. In control diet–fed 
mice, BARD1 and RAD51 overexpression increased the multiplic-
ity of experimental brain micrometastases, large brain metastases, 
and clusters of metastases (Figure 7, D–F). In contrast, the brain 
metastasis stimulatory phenotype of the two genes was abrogated 
in mice fed tempol, when metastases were quantified by any met-
ric. Overall, the data suggest that ROS constitute an endogenous 
source of DNA damage in the metastatic brain, the effects of which 
A
B
P = .08
P = .001
P = .04
P = .005
Figure  5. Effect of BARD1 and RAD51 overexpression in MDA-MB-
231-BR cells on single-cell populations during early brain colonization. 
Mice (n = 5 mice per group) were administered an intracardiac injec-
tion of 1 000 000 MDA-MB-231-BR cells transfected with vector, BARD1, 
or RAD51. On days 3, 7, and 12 after injection, metastatic cells in the 
brain were visualized by Prussian blue stain of iron oxide–labeled sin-
gle cells. A) A representative image is shown with a solitary cancer cell 
indicated by the arrow. Scale bar = 100 μm. B) The number of single 
Prussian blue cells per section with 95% confidence intervals are pre-
sented. Two-sided, multiplicity adjusted P values are presented based 
on one-way analysis of variance with Dunnett’s correction for multiple 
comparisons.
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are counteracted by tumor cell BARD1 or RAD51 overexpression 
to facilitate brain metastatic colonization.
Discussion
We report that human brain metastases of breast cancer frequently 
overexpress DNA DSB repair genes, including BARD1 and RAD51. 
Despite a robust literature outlining the contributions of RAD51 to 
DNA DSB repair and replication fork progression, RAD51 overex-
pression has only caused phenotypic changes in tumor cells in the 
context of chemotherapeutic or radiation-induced damage (24–29). 
To our knowledge, we present the first evidence for a direct bio-
logical phenotype of RAD51 or BARD1 overexpression in cancer. 
RAD51 overexpression in two models of TN breast cancer promoted 
the formation of brain metastases, but not lung metastases, provid-
ing evidence of site specificity in the phenotype. RAD51 knockdown 
in 4T1 murine mammary cells decreased brain metastases, showing 
that RAD51 levels are limiting for metastasis. Similar trends were 
observed for BARD1 in the MDA-MB-231-BR model, and in vitro 
data suggest that overexpressed BARD1 facilitated RAD51 function.
Given our data that growth and colonization phenotypes in 
vitro were dependent on a DNA-damaging agent, doxorubicin, 
A
B C D
GE F
1.0 3.1 
RAD51 
-Tubulin 
Vector   RAD51 Scramble  shRAD51 
1.0 0.11 
NS
NS
P = .02
P = .006
P = .001
P = .001
Figure 6. Effect of RAD51 expression level in 4T1-BR cells on brain and 
lung metastasis development. A) Western blot confirming overexpres-
sion and short hairpin RNA (shRNA–mediated knockdown of RAD51 in 
brain metastatic murine 4T1-BR mammary carcinoma cells is shown. 
Alpha-Tubulin was used as the loading control. Numbers indicate the 
expression fold changes relative to Alpha-Tubulin. The effect of RAD51 
overexpression on the multiplicity of brain micrometastases (B) and 
large brain metastases (C) 2 weeks after intracardiac injection was 
assessed (as described in Figure 4). The mean counts per section with 
95% confidence intervals are shown. D) In an experimental lung metas-
tasis assay after tail-vein injection of vector and RAD51 transfectants, 
the effect of RAD51 overexpression in 4T1-BR cells on multiplicity of 
lung surface metastases was determined. Individual lung counts with 
median are shown. NS = not significant. E and F) In the brain metas-
tasis assay, the effects of RAD51 knockdown reduced the multiplicity 
of brain micrometastases (E) and large brain metastases (F) compared 
with scrambled shRNA controls. Data are presented as mean counts 
per section with 95% confidence intervals. G) A similar lung metastasis 
experiment with 4T1-BR cells was done. P values presented are two-
sided and based on unpaired t tests. For all metastasis assays, 10 mice 
per group were injected.
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Figure 7. Effect of reactive oxygen species (ROS) in the brain on metas-
tasis-promoting phenotype of BARD1 and RAD51 overexpression. A) 
Normal uninvolved brain (left) and experimental MDA-MB-213-BR 
brain metastases with the surrounding neuro-inflammatory microen-
vironment (center, right) were stained with dihydroethidium (DEH). 
Superoxide dismutase (SOD) treatment (500 U/mL) was done to show 
staining specificity (right). Scale bar = 100 μm. B) Resistance to hydro-
gen peroxide (H2O2) in BARD1 and RAD51 transfectants was determined 
by clonogenic survival assays after five repeated treatments with 0, 
2.5, or 5.0  μM of H2O2. Mean percentage surviving colonies relative 
to untreated ± standard deviation are shown. P values are based on 
two-sided, unpaired t tests corrected for multiple comparisons by the 
Holm–Sidak method. C) ROS levels in brains of mice treated with a SOD 
mimetic, tempol, were measured by DHE staining of brain sections 
containing experimental MDA-MB-213-BR brain metastases. Scale 
bar  =  100  μm. D−F) An intracardiac-injected MDA-MB-231-BR experi-
mental brain metastasis assay was done. Mice were randomized to con-
trol chow or chow containing 10 g/kg diet of tempol, both containing 
flavor additive. Effects of BARD1 and RAD51 overexpression on micro-
metastasis (D) and large metastasis (E) multiplicity was determined. 
Mean counts per section with 95% confidence intervals are shown. F) 
Effects on brain metastasis cluster multiplicity (as described in Figure 4) 
by BARD1 and RAD51 overexpression in mice maintained on control 
diet or tempol diet were assessed. Mean clusters per section with 95% 
confidence intervals are shown. Two-sided, multiplicity adjusted P val-
ues are based on one-way analysis of variance with Dunnett’s correction 
for multiple comparisons. For all metastasis assays, 10 mice per group 
were injected.
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we hypothesized that the brain may require increased DNA repair 
function in cancer progression because of an endogenous source 
of genotoxic stress. ROS cause a variety of DNA lesions, many of 
which can lead to DSB (56). The brain has high levels of endog-
enous ROS, and our data demonstrated that in both MDA-MB-
231-BR tumor cells and the metastatic microenvironment, ROS 
levels are still higher. Tempol, a superoxide dismutase mimic (55), 
reduced the ROS expression in brain metastases and their micro-
environment and abrogated the brain metastasis stimulatory 
effects of BARD1 and RAD51 overexpression. Quantitatively, the 
tempol data suggest that nearly the full phenotype of promoting 
brain metastasis initiation by BARD1 and RAD51 overexpression is 
explained by resisting the effects of ROS in the brain. The effect of 
RAD51 or BARD1 overexpression was observed at early points in 
brain colonization, suggesting that ROS control initial outgrowth 
of metastases.
A limitation of our study is the relatively small size of our dis-
covery cohort, in which we collected 23 matched sets of brain 
metastases and primary breast tumors from the same women. We 
were able to identify the strong signal of DNA repair gene over-
expression in brain metastases, but weaker trends in other path-
ways, as well as subgroup-specific genes, likely elude us because of 
statistical constrains with small numbers. These matched sets are 
rare sample sets because brain metastases are infrequently resected 
and primary tumors precede a brain metastases diagnosis by long 
periods of time. Other limitations in our investigation were tech-
nical in nature. For instance, knockdown of BARD1 and RAD51 
was uniformly lethal in MDA-MB-231-BR cells. Even in 4T1-BR 
cells, which tolerated shRNA-mediated RAD51 knockdown, sta-
ble reduction in BARD1 expression could not be achieved. Lastly, 
tempol treatment was associated with increases in brain metastasis 
multiplicity, while simultaneously suppressing proliferation of the 
lesions. It is uncertain whether the suppressed proliferation was on 
or off target and whether other brain-permeable antioxidants will 
demonstrate similar effects. From a patient’s perspective, this ques-
tion warrants further study.
Our study raises a number of clinically relevant questions: Is the 
DNA repair gene expression status of primary tumors predictive 
of more frequent or faster brain relapse? Is this measure associated 
with response to treatment modalities such as focal or whole-brain 
radiation therapy? And, do differences in inflammatory and/or 
oxidative brain status between different patient populations affect 
their risk of brain relapse? Together, these data demonstrate that 
the brain metastasis–promoting phenotype of BARD1 and RAD51 
overexpression is conditional on ROS generated in the brain meta-
static microenvironment, identifying a new molecular pathway–
promoting specific pattern of breast cancer aggressiveness that is 
amenable to therapeutic development.
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